VEGFA and respiratory system disorder: When exploring the causes of mortality, while anti‐VEGF therapy in adults has been linked to vascular adverse events (Avery & Gordon, 2016; Ueta et al., 2014), our study indicates that in infants, respiratory diseases are the primary cause of mortality in both treatment groups, with a notably higher incidence in those treated with anti‐VEGF (Figure S2).